* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5JD0 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Days Payable distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's Days Payable falls into.
ExpreS2ion Biotech Holding AB Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a Days Payable of 246.47 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ExpreS2ion Biotech Holding AB and its competitors. This is 13% above median its historical median of 218.30. Over the past decade, ExpreS2ion Biotech Holding AB's Days Payable has ranged from 71.40 to 700.03. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #240 out of 702 companies in the Biotechnology industry, placing it in the top 34.2%.
Is ExpreS2ion Biotech Holding AB's Days Payable too high?
ExpreS2ion Biotech Holding AB's current Days Payable of 246.47 is 13% above median its 10-year median of 218.30. Over the past 10 years, this metric has ranged from a low of 71.40 to a high of 700.03. The Biotechnology industry median Days Payable is 113.56. ExpreS2ion Biotech Holding AB's value of 246.47 is 117% above this industry median. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #240 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #240 out of 702 companies for Days Payable. This puts ExpreS2ion Biotech Holding AB in the upper half of its industry. The industry median Days Payable is 113.56. ExpreS2ion Biotech Holding AB's value of 246.47 is 117% above this benchmark. Historically, ExpreS2ion Biotech Holding AB's own Days Payable has ranged from 71.40 to 700.03 over the past decade. While the company's 10-year median is 218.30 vs. the industry median of 113.56, ExpreS2ion Biotech Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ExpreS2ion Biotech Holding AB's current Days Payable of 246.47 is 117% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ExpreS2ion Biotech Holding AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ExpreS2ion Biotech Holding AB's current Days Payable is 246.47, which is 13% above median its own 10-year median of 218.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a current Days Payable of 246.47. The stock's GF Value™ is €0.09, compared to a current price of €0.04 — trading 61.1% below its estimated fair value. The current Days Payable is 246.47, which is 13% above median its 10-year median of 218.30 and 117% above the Biotechnology industry median of 113.56. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current Days Payable is 246.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of €0.04 is trading 61.1% below its estimated GF Value™ of €0.09.
Key valuation signals for FRA:5JD0:
Days Payable: 246.47 (13% above median its 10-year median of 218.30)
GF Value™: €0.09 vs. price of €0.04 (61.1% below fair value)
Industry Position: 117% above the Biotechnology median (#240 of 702)
No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB Business Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score
Get the complete analysis for FRA:5JD0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5JD0 has been successfully added to your 
